Baidu
map

Nat Commun:多基因危险评分(PHS)评估前列腺癌风险等级

2021-03-01 xiaozeng MedSci原创

前列腺癌是全球男性中第二大最常见的癌症,其会导致大量的发病和死亡。

前列腺癌是全球男性中第二大最常见的癌症,其会导致大量的发病和死亡。前列腺癌的筛查可降低发病率和死亡率,针对性和个性化的诊断策略有利于避免疾病的过度诊断和过度治疗。

既往研究显示,遗传风险分级有望用于确定易患癌症的个体,而多基因模型可用于评估疾病发展的总体风险。多基因危险评分与前列腺癌患者确诊时的年龄相关,并能够提高欧洲人的筛查准确性。

在该研究中,研究人员在80,491名男性(49,916例前列腺患者和30,575名对照)的多族裔数据集中评估了多基因危险评分(PHS)的效果。结果显示,PHS评分与被诊断为任何侵略性癌症(格里森评分≥7、T3-T4期、PSA≥10ng/ mL或淋巴结转移/远处转移)和前列腺癌特异性死亡患者的年龄相关。

PHS与前列腺癌的关系

结果显示,在欧洲(n=71,856)、亚洲(n=2,382)和非洲(n=6,253)人群中,癌症的关联性非常显著,前列腺癌的风险比分别为:5.54、4.49和2.54。而前列腺癌、侵袭性癌症和前列腺癌特定死亡的风险比分别为5.32、5.88和5.68。


总而言之,该研究通过多基因危险评分在多族裔数据集中对男性前列腺癌患者进行了风险分级,以评估其是否患有任何侵略性和致命性前列腺癌。该数据集还包括了患者的长期随访信息,以进一步的评估PHS与致命性前列腺癌的关联性。


原始出处:

Huynh-Le, MP., Fan, C.C., Karunamuni, R. et al. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun 12, 1236 (23 February 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2022-01-14 ms4000001063731018

    努力学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-10-31 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-10-23 liye789132251
  6. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-09-19 syscxl
  7. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-03-02 科研科研科研

    多基因危险评分评估前泪腺癌风险等级

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-03-02 ms4000000489719759

    学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1184412, encodeId=369411844129a, content=努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c85451446, createdName=ms4000001063731018, createdTime=Fri Jan 14 22:47:53 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022591, encodeId=34fd2022591f2, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Mar 17 14:40:38 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061996, encodeId=00462061996da, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon May 31 04:40:38 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087940, encodeId=2d5a208e940c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Oct 31 03:40:38 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885024, encodeId=6da31885024a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 23 01:40:38 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754460, encodeId=2d261e5446015, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Sep 19 14:40:38 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066066, encodeId=d6df2066066be, content=<a href='/topic/show?id=dd7610089477' target=_blank style='color:#2F92EE;'>#风险等级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100894, encryptionId=dd7610089477, topicName=风险等级)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Jul 03 11:40:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944757, encodeId=e7a3944e5760, content=多基因危险评分评估前泪腺癌风险等级, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Tue Mar 02 12:54:48 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944644, encodeId=be269446441e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=341c5464618, createdName=ms4000000489719759, createdTime=Tue Mar 02 08:29:24 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944631, encodeId=b03b94463187, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Mar 02 06:49:00 CST 2021, time=2021-03-02, status=1, ipAttribution=)]
    2021-03-02 易水河

    学习学习

    0

相关资讯

Nat Commun:前列腺癌患者来源的移植瘤和类器官模型对治疗的反应

前列腺癌(PCa)是全球男性中第二大最常被诊断的癌症类型和第五大癌症相关死亡原因。

Clin Cancer Res:前列腺癌中恩杂鲁胺耐药性的出现与BCL-2和IKKB依赖性有关

虽然恩杂鲁胺(ENZ)已被广泛用于治疗新生或去势抵抵抗转移性前列腺癌,但耐药性的产生和疾病的进展最终不可避免。

盘点:近期前列腺癌相关机制进展(四)

【1】Cell Death & Disease:BTF3在前列腺癌中具有致癌活性

Clin Cancer Res:对3334名晚期前列腺癌患者的循环肿瘤DNA进行基因组学分析确定了可靶向的BRCA变异和AR耐药机制

综合基因组图谱(CGP)对于转移去势抗性前列腺癌(mCRPC)患者的价值越来越大。mCRPC往往会转移到骨骼,组织活检难以进行。最近,有研究人员假设无细胞循环肿瘤DNA(ctDNA)的CGP可以提供一

JAHA:医学去势对前列腺癌患者恶性心律失常的影响

医学去势延长了大多数前列腺癌患者的QT/QTc间隔,即使在治疗前没有QT间期延长风险的患者,也可能导致TdP/VFs。QTc间隔时间较治疗前增加超过50 ms可能是发生TdP/VF的预测因素。

盘点:近期前列腺癌治疗进展(四)

【1】Prostate Cancer P D:非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较:倾向性评分匹配研究

Baidu
map
Baidu
map
Baidu
map